Literature DB >> 475164

Attenuation of prazosin effect on cardiac output in chronic heart failure.

S B Arnold, R L Williams, T A Ports, R A Baughman, L Z Benet, W W Parmley, K Chatterjee.   

Abstract

The persistence of the hemodynamic effects of prazosin was studied in 12 patients with chronic congestive heart failure. Multidose evaluation involving five 5-mg doses showed the initial decrease in systemic vascular resistance and increase in cardiac index, stroke work index, and stroke volume index to be transient. Doubling the dose did not restore effect. Modest decreases in pulmonary capillary-wedge and mean arterial pressures persisted throughout the study. In six patients, plasma prazosin concentration measured at times of hemodynamic observations showed the initial hemodynamic effect of prazosin to attenuate upon further administration despite mean plasma concentrations that exceeded those measured after the first dose. In patients with chronic heart failure, resting hemodynamic studies suggest a rapid attenuation of prazosin-mediated hemodynamic effect in the presence of adequate plasma concentration. Recognizing this phenomenon, if long-term prazosin therapy for congestive heart failure is contemplated, we suggest the hemodynamic response in individual patients be monitored.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 475164     DOI: 10.7326/0003-4819-91-3-345

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  15 in total

1.  Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.

Authors:  G L Bartels; W J Remme; A C Wiesfeld; F J Kok; M P Look; X H Krauss; H A Kruyssen
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

2.  Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function.

Authors:  B Silke; A V Zezulka; S P Verma; T C Tham; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 3.  Selection of vasodilator drugs for patients with severe chronic heart failure: an approach based on a new classification.

Authors:  M Packer
Journal:  Drugs       Date:  1982-07       Impact factor: 9.546

4.  Mortality in congestive heart failure: effects of vasodilator therapy.

Authors:  A D Timmis
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-14

Review 5.  Current concepts in the treatment of congestive heart failure.

Authors:  T B Levine
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

6.  Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.

Authors:  B M Massie; B Kramer; E Shen; F Haughom
Journal:  Br Heart J       Date:  1981-04

Review 7.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

8.  Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.

Authors:  J Vincent; W Dachman; T F Blaschke; B B Hoffman
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

9.  Immediate and sustained haemodynamic effects of prazosin during upright exercise in man.

Authors:  B Silke; W G Hendry; S H Taylor
Journal:  Br Heart J       Date:  1981-12

10.  Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.

Authors:  G J Wenting; A J Man in't veld; A J Woittiez; F Boomsma; K Laird-Meeter; M L Simoons; P G Hugenholtz; M A Schalekamp
Journal:  Br Heart J       Date:  1983-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.